A PHASE 1/1B, OPEN-LABEL, MULTICENTER, REPEAT-DOSE, DOSE-SELECTION STUDY OF CPI-444 AS SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH SELECTED INCURABLE CANCERS
- Registry ID
- CPI-444-001
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- CORVUS PHARMACEUTICALS INC
- Start date
- 2017-01-31
- Completion date
- 2021-05-26
- Last update
- 2016-03-09
Conditions
- PROSTATE CANCER
- BREAST CANCER METASTATIC TRIPLE NEGATIVE
- COLORECTAL CARCINOMA
- MELANOMA
- HEAD AND NECK CANCER
- ARTICULAR CARTILAGE INJURY
- BLADDER CANCER
- RENAL CELL CARCINOMA METASTATIC
- NON-SMALL CELL LUNG CANCER
Related clinical trials
- A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ADJUVANT INTISMERAN AUTOGENE PLUS SUBCUTANEOUS PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA MK-3475A) OR INTISMERAN AUTOGENE MONOTHERAPY VERSUS PLACEBO IN PARTICIPANTS WITH COMPLETELY RESECTED HIGH-RISK STAGE I NON-SMALL CELL LUNG CANCER (INTERPATH-014)
- A PHASE I/II OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF AZD6621, A T -CELL-ENGAGING ANTIBODY THAT TARGETS STEAP2, CD3, AND CD8 IN ADULT PARTICIPANTS WITH METASTATIC PROSTATE CANCER (ACTIVATED-4-PC)
- Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF ADJUVANT MK-1084 PLUS SUBCUTANEOUS PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA (MK-3475A) VERSUS ADJUVANT PLACEBO PLUS MK-3475A IN PARTICIPANTS WITH COMPLETELY RESECTED STAGE IIA-IIIB (N2), KRAS G12C-MUTANT NON-SMALL CELL LUNG CANCER FOLLOWING RECEIPT OF EITHER NEOADJUVANT PEMBROLIZUMAB PLUS CHEMOTHERAPY OR ADJUVANT CHEMOTHERAPY (KANDLELIT-013)
- KONTRAST-R: AN OPEN-LABEL, MULTI-CENTER, ROLLOVER STUDY FOR PARTICIPANTS WHO HAVE BEEN PREVIOUSLY ENROLLED INTO A NOVARTIS-SPONSORED OPNURASIB (JDQ443) STUDY AND ARE CONTINUING TO BENEFIT FROM OPNURASIB AS A SINGLE AGENT OR IN COMBINATION WITH OTHER STUDY TREATMENTS
- Electrochemotherapy-Induced Changes in Tumor Microenvironment in Cutaneous Melanoma
View on source registry